You are here:

Genitourinary, Renal and Prostate Clinical Trials

 

Study Name:

Randomized Phase III Comparing Everolimus Plus Placebo versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing after Treatment with Tyrosine Kinase Inhibitors

         

Purpose:

This randomized phase III trial is studying giving everolimus together with bevacizumab to see how well it works compared to everolimus alone in treating patients with advanced kidney cancer that progressed after first-line therapy.

Study Type: Treatment

Protocol: UIC 2011-0372 CALGB 90802

 

 For study details, click here.

Internal users only: click here for protocol details and forms.

Study Name:

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to the Bone.

         

Purpose:

This randomized phase III trial is studying how well zoledronate works in preventing bone-related events in patients who are receiving androgen deprivation therapy for prostate cancer and bone metastases.

Study Type: Treatment

Protocol: UIC 2004-0677 CALGB 90202

 

 For study details, click here.

Internal users only: click here for protocol details and forms.

Study Name:

A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab versus Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer that have Received Prior Treatment with Docetaxel.

         

Purpose:

The purpose of the study is to determine if advanced prostate cancer patient s that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone.

Study Type: Treatment

Protocol: UIC 2010-0792 CA 184-043-0203

 

 For study details, click here.

Internal users only: click here for protocol details and forms

Study Name:

Identification of Class I HLA-restricted Prostatic Epitopes for Specific T Cell Immunotherapy of Human Prostate Cancer.

         

Purpose:

To determine whether class I HLA-restricted T cells with specificity for identified prostatic epitopes lyse tumor cells.

Protocol: UIC 1999-0599

 

Internal users only: click here for protocol details and forms

Back to Oncology Clinical Trials Homepage